Tag: pyrrolobenzodiazepine (PBD) dimer
Advances in the Development of Dual-Drug Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).
U.S. FDA Accepts Biologics License Application and Grants Priority Review for...
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402.
The investigational agent is...
Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients...
A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination with azacitidine (Vidaza®; Celgene Corporation) in patients with...
